AMH
CLDI.WS

Apollo Management Holdings’s Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 CLDI.WS Stock Holding History

Apollo Management Holdings’s Portfolio CLDI.WS Stock Details CLDI.WS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-967,726
Closed -$348K – 332
2022
Q1 		$348K Sell
967,726
-22,273
-2% -$9.81K ﹤0.01% 278
2021
Q4 		$495K Buy
+989,999
New +$558K ﹤0.01% 209

Other funds holding CLDI.WS

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Apollo Management Holdings's CLDI.WS Position: Q2 2022 in Review

Apollo Management Holdings sold out of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) in Q2 2022, closing a stake of 967,726 shares — an estimated $348K sold.

Apollo Management Holdings first reported a position in CLDI.WS in Q4 2021 and held it in 2 quarters. The position peaked at $495K in Q4 2021. 26 funds tracked by Wall St. Rank hold CLDI.WS as of Q2 2022.

  • Apollo Management Holdings reported no remaining Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position as of Q2 2022 after selling out during the quarter.
  • Apollo Management Holdings sold 967,726 Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 shares in Q2 2022, an estimated $348K.
  • Apollo Management Holdings first reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in Q4 2021 and held it in 2 quarters.
  • Apollo Management Holdings's Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position peaked at $495K in Q4 2021.
  • 26 funds tracked by Wall St. Rank held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 as of Q2 2022.

Based on Apollo Management Holdings's 13F filing for Q2 2022, filed 16 Aug 2022.